Welcome!

News Feed Item

Product Clearance, Appointments, Upcoming Financial Results, and Clinical Study Results - Analyst Notes on Covidien, Medivation, United Therapeutics, Questcor and CareFusion

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, April 25, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Covidien plc (NYSE: COV), Medivation, Inc. (NASDAQ: MDVN), United Therapeutics Corporation (NASDAQ: UTHR), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1611-100free.

--
Covidien plc Analyst Notes
On April 14, 2014, Covidien plc (Covidien) announced the U.S. Food and Drug Administration (FDA) Clearance for the Kangaroo™ feeding tube with Integrated Real-time Imaging System (IRIS) Technology, the first-of-its-kind camera-equipped disposable feeding tube designed to enhance patient safety. The Company stated that the Covidien IRIS streams a real-time video back to the monitor, providing visual information that aids clinicians in identifying key areas of a patient's anatomy and also enables medical professionals in saving images from the live stream and making notes associated with the image. Jim Clemmer, President, Medical Supplies, Covidien, said, "Covidien is an industry leader in nutritional delivery and enteral feeding devices and products such as the Kangaroo feeding tube with IRIS technology are designed to help improve patient outcomes and set new expectations for medical device product safety and innovation around the world." The full analyst notes on Covidien are available to download free of charge at:

http://www.analystsreview.com/1611-COV-25Apr2014.pdf

--
Medivation, Inc. Analyst Notes
On April 17, 2014, Medivation, Inc. (Medivation) announced the appointment of Patrick Machado to the Company's Board of Directors, who recently retired as the Chief Financial and Business Officer. Commenting on the appointment, Kim D. Blickenstaff, Chairman, Medivation, said, "For the past nine years of having the honor of serving on the board of directors of Medivation, including seven as chairman, I've had the opportunity to observe the keen insight and vision that Pat Machado has brought to Medivation. I look forward to working with Pat in his new role, as he continues to help guide Medivation's efforts to develop novel therapies for serious diseases." The full analyst notes on Medivation are available to download free of charge at:

http://www.analystsreview.com/1611-MDVN-25Apr2014.pdf

--
United Therapeutics Corporation Analyst Notes
On April 22, 2014, United Therapeutics Corporation (United Therapeutics) announced that it will release its Q1 2014 financial results on April 29, 2014, before the market opens. The Company added that it will hold a half-hour teleconference on April 29, 2014, at 9:00 a.m. ET. United Therapeutics stated that the teleconference will be webcast and can be accessed via its website. The full analyst notes on United Therapeutics are available to download free of charge at:

http://www.analystsreview.com/1611-UTHR-25Apr2014.pdf

--
Questcor Pharmaceuticals, Inc. Analyst Notes
On April 21, 2014, Questcor Pharmaceuticals, Inc. (Questcor) announced results from an investigator-initiated clinical study that examined the dosing and effectiveness of H.P. Acthar® Gel in 20 patients with nephrotic syndrome due to idiopathic membranous nephropathy (iMN). According to the Company, the results demonstrated that Acthar Gel is proven to be a potentially useful therapy for inducing remission of proteinuria in patients suffering from nephrotic syndrome secondary to iMN. Questcor added that the study also showed that the clearance of anti-PLA2R antibodies, an immunological marker of iMN disease activity, preceded or paralleled improvements in proteinuria as a result of Acthar treatment in patients with detectable antibody levels. The Company further stated that Acthar Gel was well tolerated by patients during the course of the study, with the most common side effects being mood changes, weight gain, and transient insomnia. The full analyst notes on Questcor are available to download free of charge at:

http://www.analystsreview.com/1611-QCOR-25Apr2014.pdf

--
CareFusion Corporation Analyst Notes
On April 7, 2014, CareFusion Corporation (CareFusion) announced that it plans to release its Q3 FY 2014 financial results on May 5, 2014, after the close of trading on the New York Stock Exchange. The Company added that it will also host a conference call on the same day at 2:00 p.m. PDT (5:00 p.m. EDT). CareFusion stated that the call will be made accessible through the Investors Page of the Company website. The full analyst notes on CareFusion are available to download free of charge at:

http://www.analystsreview.com/1611-CFN-25Apr2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
SYS-CON Events announced today that CollabNet, a global leader in enterprise software development, release automation and DevOps solutions, will be a Bronze Sponsor of SYS-CON's 20th International Cloud Expo®, taking place from June 6-8, 2017, at the Javits Center in New York City, NY. CollabNet offers a broad range of solutions with the mission of helping modern organizations deliver quality software at speed. The company’s latest innovation, the DevOps Lifecycle Manager (DLM), supports Value S...
The Internet of Things is clearly many things: data collection and analytics, wearables, Smart Grids and Smart Cities, the Industrial Internet, and more. Cool platforms like Arduino, Raspberry Pi, Intel's Galileo and Edison, and a diverse world of sensors are making the IoT a great toy box for developers in all these areas. In this Power Panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists discussed what things are the most important, which will have the most profound e...
Multiple data types are pouring into IoT deployments. Data is coming in small packages as well as enormous files and data streams of many sizes. Widespread use of mobile devices adds to the total. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists will look at the tools and environments that are being put to use in IoT deployments, as well as the team skills a modern enterprise IT shop needs to keep things running, get a handle on all this data, and deli...
Automation is enabling enterprises to design, deploy, and manage more complex, hybrid cloud environments. Yet the people who manage these environments must be trained in and understanding these environments better than ever before. A new era of analytics and cognitive computing is adding intelligence, but also more complexity, to these cloud environments. How smart is your cloud? How smart should it be? In this power panel at 20th Cloud Expo, moderated by Conference Chair Roger Strukhoff, pane...
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
SYS-CON Events announced today that Progress, a global leader in application development, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Enterprises today are rapidly adopting the cloud, while continuing to retain business-critical/sensitive data inside the firewall. This is creating two separate data silos – one inside the firewall and the other outside the firewall. Cloud ISVs oft...
SYS-CON Events announced today that Grape Up will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct. 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company specializing in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the U.S. and Europe, Grape Up works with a variety of customers from emergi...
The age of Digital Disruption is evolving into the next era – Digital Cohesion, an age in which applications securely self-assemble and deliver predictive services that continuously adapt to user behavior. Information from devices, sensors and applications around us will drive services seamlessly across mobile and fixed devices/infrastructure. This evolution is happening now in software defined services and secure networking. Four key drivers – Performance, Economics, Interoperability and Trust ...
@ThingsExpo has been named the Most Influential ‘Smart Cities - IIoT' Account and @BigDataExpo has been named fourteenth by Right Relevance (RR), which provides curated information and intelligence on approximately 50,000 topics. In addition, Right Relevance provides an Insights offering that combines the above Topics and Influencers information with real time conversations to provide actionable intelligence with visualizations to enable decision making. The Insights service is applicable to eve...
Building a cross-cloud operational model can be a daunting task. Per-cloud silos are not the answer, but neither is a fully generic abstraction plane that strips out capabilities unique to a particular provider. In his session at 20th Cloud Expo, Chris Wolf, VP & Chief Technology Officer, Global Field & Industry at VMware, will discuss how successful organizations approach cloud operations and management, with insights into where operations should be centralized and when it’s best to decentraliz...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
Cybersecurity is a critical component of software development in many industries including medical devices. However, code is not always written to be robust or secure from the unknown or the unexpected. This gap can make medical devices susceptible to cybersecurity attacks ranging from compromised personal health information to life-sustaining treatment. In his session at @ThingsExpo, Clark Fortney, Software Engineer at Battelle, will discuss how programming oversight using key methods can incre...
The goal of Continuous Testing is to shift testing left to find defects earlier and release software faster. This can be achieved by integrating a set of open source functional and performance testing tools in the early stages of your software delivery lifecycle. There is one process that binds all application delivery stages together into one well-orchestrated machine: Continuous Testing. Continuous Testing is the conveyor belt between the Software Factory and production stages. Artifacts are ...
In recent years, containers have taken the world by storm. Companies of all sizes and industries have realized the massive benefits of containers, such as unprecedented mobility, higher hardware utilization, and increased flexibility and agility; however, many containers today are non-persistent. Containers without persistence miss out on many benefits, and in many cases simply pass the responsibility of persistence onto other infrastructure, adding additional complexity.